CORONA Remedies cash flow

Latest FY26
Cash from operations
₹229cr 
Capital spending
₹174cr 
Free cash flow
₹55.3cr 
Cash from financing
₹25.3cr 
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026
Adjustments to reconcile profit — non-cash items
—37.9
—7.0
—−7.1
—−0.1
—−1.3
—8.2
Changes in working capital
—5.2
—−26.2
—2.4
—0.0
—−14.3
—3.7
—1.4
—−3.0
—25.0
Cash from operating activities
271240
—38.5
—279
—49.4
—229
Cash from investing activities
—174
—0.5
—7.1
—−89.6
—−256
Cash from financing activities
—44.7
—116
—36.0
—5.3
—−4.9
—25.3
—−1.4
—−1.4
Reference items
334293
21.4%20.9%
55.355.3
₹9.05₹9.05
245.06×—
—1.24×
—49.4
—5.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CORONA₹2,217.40

CORONA Remedies Ltd.

· Pharma & Health
₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,562 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation37.9—
+ Finance Costs7.0—
+ Interest Income-7.1—
+ Fair Value (Gains) / Losses-0.1—
+ Unrealised FX (Gain) / Loss-1.3—
+ Other Reconciling Items8.2—
Changes in Working Capital
+ Inventories5.2—
+ Trade Receivables — Current-26.2—
+ Other Financial Assets — Current2.4—
+ Other Financial Assets — Non-current0.0—
+ Other Current Assets-14.3—
+ Trade Payables — Current3.7—
+ Other Financial Liabilities — Current1.4—
+ Other Current Liabilities-3.0—
+ Provisions — Current25.0—
Cash from Operating Activities
Profit Before Tax (per I/S)240.4270.9
+ Total Adjustments (incl. Working Capital)38.5—
Cash from Operations (pre-tax)278.9—
+ Income Taxes Paid49.4—
Cash from Operating Activities229.5—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)174.1—
+ Disp of Fixed Assets0.5—
+ Interest Received — Investing7.1—
+ Other Inflows / (Outflows) — Investing-89.6—
Cash from Investing Activities-256.2—
Cash from Financing Activities
+ Payments for Other Equity Instruments44.7—
+ Proceeds from Borrowings116.2—
+ Repayment of Borrowings36.0—
+ Interest Paid5.3—
+ Other Inflows / (Outflows) — Financing-4.9—
Cash from Financing Activities25.3—
Net Changes in Cash (pre-FX)-1.4—
Net Changes in Cash-1.4—
Reference Items
EBITDA293.4334.3
EBITDA Margin %20.9121.44
Free Cash Flow (CFO − Capex)55.355.3
Free Cash Flow per Basic Share9.059.05
Price to Free Cash Flow—245.06
Cash Flow to Net Income1.24—
Cash Paid for Taxes49.4—
Cash Paid for Interest5.3—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.